OpenEvidence, an AI platform often described as “ChatGPT for doctors,” has raised $200 million at a $6 billion valuation, according to The New York Times. The funding round comes only three months after the company’s previous $210 million raise at a $3.5 billion valuation, highlighting growing investor interest in specialized AI tools.
Trained on trusted medical sources like JAMA and the New England Journal of Medicine, OpenEvidence helps medical professionals quickly access verified medical information to assist in patient care. The tool is currently free for verified doctors and nurses, supported by advertising.
Since its launch in 2022, OpenEvidence’s growth has surged, with monthly clinical consultations reaching 15 million, nearly doubling since July.
Related: X Launches Marketplace for Inactive Handles
The latest funding round was led by Google Ventures, with participation from major firms including Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft.
